Clinical trial · Observational
Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs
Impact of Circulating Tumor DNA on Early Cancer Detection and Evaluation of STAS in Patients With Ground Glass Opacities
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is the early and non-invasive diagnosis of lung cancer in patients with pulmonary ground glass opacity. In particular, objective of the study is to evaluate the presence or absence of circulating tumor DNA (ctDNA) on the peripheral blood of patients with evidence of ground glass opacity(GGO) at CT scan and to evaluate the role that this can play in the diagnostic / therapeutic process. The ctDNA evaluation will be performed at the first radiological finding and subsequently correlated with the malignancy of the lesion based on the radiological / histological criteria regularly used in international protocols. Secondary objective is the correlation, in patients with malignant GGO undergoing surgical treatment, of the ctDNA presence and tumor spread through the air spaces (STAS), and its correlation with local relapses.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cell | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Spreading of Tumor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cf DNA and ct DNA | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Malignant GGOs
- description
- Patients with histologically proven malignant pulmonary ground glass opacities (GGOs)
- interventionNames
- Diagnostic Test: cf DNA and ct DNA
- label
- Benign GGOs
- description
- Patients with histologically or radiologically proven benign pulmonary ground glass opacities (GGOs)
- interventionNames
- Diagnostic Test: cf DNA and ct DNA
Primary outcomes (2)
- measure
- Quantification of cf DNA
- timeFrame
- through study completion, an average of 2 year
- description
- Assess quantity of the circulating free DNA measured in ng/μL using Qubit 2.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age\> 18 years * radiological finding of pulmonary ground glass opacity * absence of solid or haematological tumor Exclusion Criteria: * radio / chemotherapy treatment for at least 6 months * patient unable to understand and express his consent to the study
References
Publications (0)
Data not yet available